| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/26/2005 | EP1499888A2 Conformationally constrained peptides that bind the orl-1 receptor |
| 01/26/2005 | EP1499886A1 Methods and compositions for inducing an immune response |
| 01/26/2005 | EP1499746A1 Method to inhibit cell growth using oligonucleotides |
| 01/26/2005 | EP1499735A2 Optimization of transgene expression in mammalian cells |
| 01/26/2005 | EP1499732A2 Essential and important genes of pseudomonas aeroginosa and the use thereof to design or identify antibacterial agents |
| 01/26/2005 | EP1499731A2 Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
| 01/26/2005 | EP1499730A1 Immunoconjugates for the treatment of tumours |
| 01/26/2005 | EP1499729A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 01/26/2005 | EP1499724A1 Derivatives of the il-2 receptor gamma chain, their production and use |
| 01/26/2005 | EP1499721A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription factors |
| 01/26/2005 | EP1499719A1 FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
| 01/26/2005 | EP1499718A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/26/2005 | EP1499639A1 Novel nucleic acid sequences and proteins of tumors and neoplasias of the thyroid gland |
| 01/26/2005 | EP1499636A2 Neurotrophic and neuroprotective peptides |
| 01/26/2005 | EP1499635A2 Teneurin c-terminal associated peptides (tcap) and uses thereof |
| 01/26/2005 | EP1499633A2 Hagfish cathelin-associated antimicrobial peptides and genes |
| 01/26/2005 | EP1499631A2 Rna interference mediated inhibition of tgf-beta and tgf-beta receptor gene expression using short interfering nucleic acid (sina) |
| 01/26/2005 | EP1499628A2 Rna interference mediated inhibition of stearoyl-coa desaturase (scd) gene expression using short interfering nucleic acid (sina) |
| 01/26/2005 | EP1499362A1 Fusions of cytokines and tumor targeting proteins |
| 01/26/2005 | EP1499358A1 Ph-sensitive polymer |
| 01/26/2005 | EP1499357A1 Treatment of metabolic syndrome |
| 01/26/2005 | EP1499356A1 Methods of treatment and diagnosis of patients with hepatitis c infection |
| 01/26/2005 | EP1499354A2 Methods of using cytokine antagonists to treat hiv infection and aids |
| 01/26/2005 | EP1499350A2 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 01/26/2005 | EP1499349A2 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 01/26/2005 | EP1499347A2 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| 01/26/2005 | EP1499346A2 Treatment of type 1 diabetes before and after expression of predisposition markers |
| 01/26/2005 | EP1499345A2 Protein a compositions and methods of use |
| 01/26/2005 | EP1499344A1 Medical device |
| 01/26/2005 | EP1499343A1 A method of modulating cellular activity |
| 01/26/2005 | EP1499342A2 Therapeutic composition for treatment of cancer by arginine depletion |
| 01/26/2005 | EP1499340A2 Proteins involved in the regulation of energy homeostasis |
| 01/26/2005 | EP1499339A1 Anti-inflammatory and wound healing effects of lymphoid thymosin beta 4 |
| 01/26/2005 | EP1499337A1 Immunotherapeutic and immunoprophylactic reagents |
| 01/26/2005 | EP1499336A2 Protease inhibitors |
| 01/26/2005 | EP1499332A2 Compositions and methods for treating cancer with an oncolytic viral agent |
| 01/26/2005 | EP1499327A2 Beta -amyloid peptide-binding proteins and polynucleotides encoding the same |
| 01/26/2005 | EP1499324A1 Method for treating and preventing hyperparathyroidism |
| 01/26/2005 | EP1499323A1 Treatment of hypertension in women receiving hormone replacement therapy |
| 01/26/2005 | EP1499296A1 Formulation of fine particles using liquefied or dense gases |
| 01/26/2005 | EP1499294A2 Transport system in biological systems |
| 01/26/2005 | EP1499284A1 Biologically active compounds for the modification of bodily odours |
| 01/26/2005 | EP1499277A2 Modification of feeding behavior |
| 01/26/2005 | EP1499190A2 Methods for treating liver disease and liver damage with growth hormone and foxm1b |
| 01/26/2005 | EP1499189A1 Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium |
| 01/26/2005 | EP1499187A2 Immunostimulatory g,u-containing oligoribonucleotides |
| 01/26/2005 | EP1499186A1 Use of heme oxygenase-1 and products of heme degradation |
| 01/26/2005 | EP1430140A4 Isoform-selective inhibitors and activators of pde3 cyclic |
| 01/26/2005 | EP1385881A4 Anti-obesity polypeptides |
| 01/26/2005 | EP1320359B1 Thermogelling biodegradable aqueous polymer solution |
| 01/26/2005 | EP1294921A4 Transgenically produced platelet derived growth factor |
| 01/26/2005 | EP1283047A4 Method for producing a bioactive substance from blood serum |
| 01/26/2005 | EP1280901B1 3d structure of polypeptides containing a tpr-structure motif with chaperone-binding function, crystals thereof and compounds for inhibition of said peptides |
| 01/26/2005 | EP1239867B1 Methods for treating and preventing damage to mucosal tissue |
| 01/26/2005 | EP1231926B1 Biomolecular complex formed between hyaluronic acid and a biomolecule, its method of manufacture and medical uses thereof |
| 01/26/2005 | EP1185279B1 Agents for treating malignant diseases using e1a-deficient adenoviruses with yb-1 protein-dependent replication |
| 01/26/2005 | EP1127133B1 Polypeptide mediating cell permeability |
| 01/26/2005 | EP1107981B1 Synthesis of ring-modified cyclic peptide analogs |
| 01/26/2005 | EP1017835A4 Methods of using cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy |
| 01/26/2005 | EP0996636B1 The ha-1 antigen |
| 01/26/2005 | EP0934412B1 HUMAN THYMOSIN beta 15 GENE, PROTEIN AND USES THEREOF |
| 01/26/2005 | EP0886651B1 Persephin and related growth factors |
| 01/26/2005 | EP0871486B1 Diphtheria toxin epitopes |
| 01/26/2005 | EP0862637B1 Pseudomonas exotoxin - myelin basic protein chimeric proteins |
| 01/26/2005 | EP0828509B1 Composition to improve digestibility and utilisation of nutrients |
| 01/26/2005 | EP0820277B1 Powdered pharmaceutical formulations having improved dispersibility |
| 01/26/2005 | EP0769968B1 Retroviral vectors produced by producer cell lines resistant to lysis by human serum |
| 01/26/2005 | EP0725826B1 Improvements relating to cancer therapy |
| 01/26/2005 | EP0652953B1 Morphogenic protein soluble complex and composition thereof |
| 01/26/2005 | EP0579758B1 Parathyroid hormone receptor and dna encoding same |
| 01/26/2005 | CN1571834A Cell therapy method for the treatment of tumors |
| 01/26/2005 | CN1571796A Melanocortin receptor ligands |
| 01/26/2005 | CN1571795A Synthesis of cyclosporin analogs |
| 01/26/2005 | CN1571794A Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 01/26/2005 | CN1571676A Biphasic mixtures of GLP-1 and insulin |
| 01/26/2005 | CN1571675A Treatment and diagnosis of insulin-resistant states |
| 01/26/2005 | CN1571674A Use of histamine to treat liver disease |
| 01/26/2005 | CN1571673A Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents |
| 01/26/2005 | CN1571670A Treating sexual desire disorders with flibanserin |
| 01/26/2005 | CN1571663A Dosage forms, devices and methods of treatment |
| 01/26/2005 | CN1571657A Novel cyclosporin analog microemulsion preconcentrates |
| 01/26/2005 | CN1570105A Human rapid contraction of skeletal muscle troponin ó± production and activity detection method |
| 01/26/2005 | CN1570104A Infuse protein of candida albicans hot shock protein 90 epitope and phage envelop protein , and its uses |
| 01/26/2005 | CN1570094A Extraction method for SOD complex enzyme coarse powder from corn |
| 01/26/2005 | CN1570093A Extraction method for SOD complex enzyme fine powder from corn |
| 01/26/2005 | CN1569900A Heavy chain variable region single domain antibody reinforced fusion protein VH-LDP-AE |
| 01/26/2005 | CN1569899A Recombinant nerve putrescence virus protein vaccine and its coding sequence and uses |
| 01/26/2005 | CN1569893A Antigen epitope of gold staphylococcus virulence factor regulatory protein and its mimic epitope and use thereof |
| 01/26/2005 | CN1569892A Multi-branched polyethylene glycol and protein or polypeptide combined products and their preparation method |
| 01/26/2005 | CN1569891A Micro-molecular polypeptides capable of combining with gold staphylococcus virulence factor regulatory protein and its pharmaceutical use |
| 01/26/2005 | CN1569890A Solid-phase synthesis process of octreotide acetate |
| 01/26/2005 | CN1569879A Variable region of light chain and heavy chain genes of anti-KDR monoclonal antibody and its use |
| 01/26/2005 | CN1569226A Freeze dried powder injection of hirudin and its preparation method |
| 01/26/2005 | CN1569225A Recombinant human interferon alpha nebula |
| 01/26/2005 | CN1569224A Interferon effervescence capsule for vagina used and its preparation method |
| 01/26/2005 | CN1569223A Freeze-dried interferon spray and its preparation method |
| 01/26/2005 | CN1569222A Preparation method of NGF oral capsule |
| 01/26/2005 | CN1569221A VEGF plasmid-liposome complex and its usage |
| 01/26/2005 | CN1569220A Application of gene recombined anti fungus peptide in the treatment of eumycetes infection |
| 01/26/2005 | CN1569219A Eye drop for treating amblyopia and its preparing process |